Court Upholds $115 Million Judgment in Patent Case Filed by Syntrix Biosystems against Illumina, Inc.

  Court Upholds $115 Million Judgment in Patent Case Filed by Syntrix
  Biosystems against Illumina, Inc.

     Decision Affirms Largest Patent Verdict in Washington State History

Business Wire

AUBURN, Wash. -- November 6, 2013

Syntrix Biosystems, Inc., is pleased to announce that a federal court in
Tacoma, Washington, has upheld a judgment for $115 million and an
eight-percent running royalty in a patent infringement case the company filed
against Illumina, Inc., a San Diego-based biotechnology firm. This decision
affirms the largest patent verdict in Washington state history and an award
that will likely be one of the largest of its type in the nation this year.

In an order filed on November 4^th of this year, the Court denied Illumina’s
motions for judgment as a matter of law and a new trial, ruling that the
underlying jury verdict was “the result of seven citizens’ hard work” and that
it was “supported by the evidence.”

The jury rendered that verdict on March 15, 2013, after an 11-day trial
focusing on U.S. Patent No. 6,951,682 (“the ’682 patent”), which covers
synthetic matrix and array technology invented by the founder and president of
Syntrix Biosystems, John A. Zebala, MD, PhD. The jury found that Illumina
infringed the ’682 patent and ordered the defendant to pay $96 million in
damages related to the “BeadChip” products it marketed from 2005 through May

The Court later ordered additional damages in connection with infringing sales
made by Illumina from May 2012 through the date of the verdict. The Court also
ordered payment of prejudgment interest from 2005, bringing the total judgment
against Illumina to $115 million. Finally, the Court ordered Illumina to pay
Syntrix Biosystems an ongoing royalty of eight percent for continued sales of
infringing products, a full two percent higher than the royalty found by the

The term of the ’682 patent extends to October 2019.

Syntrix Biosystems was represented at trial by attorneys with the law firms of
Bracewell & Giuliani LLP, Nix, Patterson & Roach LLP, and Foster Pepper PLLC.
The company’s case against Illumina was styled Syntrix Biosystems, Inc. v.
Illumina, Inc., Cause No. C10-5870 BHS (W.D. Wash.).

About Syntrix Biosystems, Inc.

Syntrix Biosystems, Inc., is a private, Washington-based biotechnology company
dedicated to developing and commercializing therapeutic compounds and research
platforms for the pharmaceutical, biotechnology and research markets. Since
its inception, Syntrix Biosystems has been awarded nearly $25 million from the
National Institutes of Health in support of its development efforts. For
further information, see


for Syntrix Biosystems, Inc.
Eric Wetzel, 800-933-5998